Inflammatory bowel disease and Parkinson's disease: common pathophysiological links
- PMID: 33067333
- DOI: 10.1136/gutjnl-2020-322429
Inflammatory bowel disease and Parkinson's disease: common pathophysiological links
Abstract
Inflammatory bowel disease and Parkinson's disease are chronic progressive disorders that mainly affect different organs: the gut and brain, respectively. Accumulating evidence has suggested a bidirectional link between gastrointestinal inflammation and neurodegeneration, in accordance with the concept of the 'gut-brain axis'. Moreover, recent population-based studies have shown that inflammatory bowel disease might increase the risk of Parkinson's disease. Although the precise mechanisms underlying gut-brain interactions remain elusive, some of the latest findings have begun to explain the link. Several genetic loci are shared between both disorders with a similar direction of effect on the risk of both diseases. The most interesting example is LRRK2 (leucine-rich repeat kinase 2), initially identified as a causal gene in Parkinson's disease, and recently also implicated in Crohn's disease. In this review, we highlight recent findings on the link between these seemingly unrelated diseases with shared genetic susceptibility. We discuss supporting and conflicting data obtained from epidemiological and genetic studies along with remaining questions and concerns. In addition, we discuss possible biological links including the gut-brain axis, microbiota, autoimmunity, mitochondrial function and autophagy.
Keywords: IBD - genetics; IBD basic research; Parkinson's disease; epidemiology; inflammatory bowel disease.
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: JS reports receiving speaker’s fees from Nestle Health Sciences, Abbvie and Takeda; receiving consultancy fees from Janssen. SV reports receiving speaker’s fees from AbbVie, Takeda, Genentech/Roche, Pfizer and Janssen; receiving consultancy fees from AbbVie, MSD, Takeda, Ferring, Genentech/Roche, Shire, Pfizer, Galapagos, Mundipharma, Hospira, Celgene, Second Genome, Progenity, Lilly, Arena, Gilead and Janssen; receiving financial support for research from MSD, Abbvie, Janssen and Pfizer.
Comment in
-
Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease.Gut. 2021 Oct;70(10):2010-2012. doi: 10.1136/gutjnl-2020-323482. Epub 2020 Nov 17. Gut. 2021. PMID: 33203725 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical